CD46 may influence how T cells retain potentially active HIV that could give rise to new virus. View article...

A prominent protein on most human cells may be key to unlocking the code that makes humans susceptible to pathogenic bacteria and viruses, including human immunodeficiency virus (HIV), according to a…

A prominent protein on most human cells may be key to unlocking the code that makes humans susceptible to pathogenic bacteria and viruses, including human immunodeficiency virus (HIV), according to a new study published in Science Immunology led by researchers at Purdue University and the National Heart, Lung, and Blood Institute.

A prominent protein on most human cells may be key to unlocking the code that makes humans susceptible to pathogenic bacteria and viruses, including human immunodeficiency virus (HIV), according to a ...

domani, 13 ottobre, h. 21, si officia il rito più #kitsch dell'apoesia taliana, ovvero il #premiostregapoesia . di solito ci sta pure la musica, pensa te. ...

a, Polymerase chain reaction (PCR) combined with gel electrophoresis demonstrating genomic DNA level of GGTA1, CMAH, B4GALNT2, THBD, CD46 and CD55 in PBMCs from 6-gene-edited (6-GE) and wild-type (WT) pigs. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the loading control. NTC, no template control. b-c, Sanger sequencing of the PBMC gDNA isolated from the donor and wild-type pigs, sequences of GGTA1, B4GALNT2 and CMAH of donor were compared with that of wild-type pig, and sequences of CD46, CD55 and THBD of donor were compared with that of human. d-e, The PCR combined with gel electrophoresis detecting the presence of PERV (d) as well as microchimerism (e) in the PBMCs and tissues of the recipient and the xenograft. PERV-ABC, the shared sequence of PERV-A, PERV-B and PERV-C. PERV-C, the specifical sequence of PERV-C. GAPDH was used as the control gene. Sequence of wild-type (WT) pig was used as positive control. NTC, no template control. f, The diameters of portal veins and hepatic arteries from the donor and recipient were detected by ultrasound before surgery. Source data...

Children's Health Defense deleted my interview segment after I cited peer-reviewed research confirming the measles vaccine virus was created with GOF techniques.

AbstractPurpose:. Metastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 (225Ac) have shown promising results in prostate cancer treatment, but a significant fraction of patients with advanced mCRPC demonstrate loss of PSMA expression. We have previously reported that PSMA-null and PSMA-positive tumors can be detected and treated effectively with CD46-targeted radiopharmaceuticals. This study evaluates the CD46-targeting PET imaging agent [89Zr]DFO-YS5, and the radioimmunotherapy agent [225Ac]Macropa-PEG4-YS5, in disseminated prostate cancer tumors.Experimental Design:. Microtumor lesions, primarily observed in the liver, kidneys, and lungs, were successfully detected with [89Zr]DFO-YS5 PET imaging. We used disseminated 22Rv1 tumors for biodistribution studies, dosimetry assessments, and therapeutic efficacy evaluations of [225Ac]Macropa-PEG4-YS5.Results:. Quantitative digital alpha-particle autoradiography revealed high radiation dose deposition from [225Ac]Macropa-PEG4-YS5 in microtumors compared with surrounding liver tissues, although in larger lesions (>1 mm diameter), the dose distribution was heterogeneous. Early treatment of smaller disseminated tumors with a uniform radiation dose was more effective in ablating tumors and promoting survival. In late-stage lesions of large size, heterogeneous dose deposition limited therapeutic efficacy, requiring higher administered activity to achieve a complete response.Conclusions:. Our findings highlight that [225Ac]Macropa-PEG4-YS5 holds the potential for clinical translation for metastatic prostate cancer and reinforces the value of microdosimetry in understanding the efficacy of and resistance to targeted alpha therapy.

Abstract. Radiopharmaceuticals, which emit either alpha or beta particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted alpha-particle emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus to macrometastatic disease.